Education

2001-2004   Ph.D, Institute of Bioengineering, Academy of Military Medical Sciences, Chinese PLA 

1986-1989   M.S. Biochemistry, Nanjing Agricultural University 

1982-1986   B.S.  Biology Science, Anhui Normal University

Academic Experience

2012-2024 Professor, Institute of Microbiology, Chinese Academy of Sciences, China

2004-2012 Associate Professor, Institute of Microbiology, Chinese Academy of Sciences, China

1989-2001 Associate Professor, Anhui Agricultural University, China

Research Interests

1. Antibody Screening and Drug Development: Leveraging a mature and innovative research platform for antibody drugs, we have successfully developed etesevimab, a COVID-19 monoclonal antibody drug. This groundbreaking drug has received emergency use authorization in 17 countries.

2. Antigen Design and Vaccine Development: Utilizing structural biology, we have established a cutting-edge reverse vaccinology platform. This platform spans antigen identification, antibody screening, and vaccine design. Notably, we developed the world’s first conditionally approved recombinant protein vaccine against SARS-CoV-2, featuring a unique dimeric structure.

Representative Research Achievements

1. Zeng J, Li Y, Jiang L, Luo L, Wang Y, Wang H, Han X, Zhao J, Gu G, Fang M*, Huang Q* and Yan J*. Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. Emerging Microbes & Infection 2023 Dec;12(1):2204151.

2. Shi R, Zeng J, Xu L, Wang F, Duan X, Wang Y, Wu Z, Yu D, Huang Q*, Yao Y*, and Yan J*. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core eBioMedicine. 2022;85: 104297

3. Du Y, Shi R, Zhang Y, Duan X, Li L, Zhang J, Wang F, Zhang R, Shen H, Wang Y, Wu Z, Peng Q, Pan T, Sun W, Huang W, Feng Y, Feng H, Xiao J, Tan W *, Wang Y *, Wang C *, Yan J *, A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants, Nature Communications 12(1) (2021) 5000.

4. Dai L, Xu K, Li J, Huang Q, Song J, Han Y, Zheng T, Gao P, Lu X, Yang H, Liu K, Xia Q, Wang Q, Chai Y, Qi J, Yan J*, Gao GF*. Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. Nature Immunology. 2021 Aug;22(8):958-968.

5. Shi, R, Shan C; Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu W, Wu G, Zhang B, Wang L, Qi J, Feng H, Fu-S*, Wang Q*, Gao GF*, Yuan Z*, Yan J*. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020, 584:120-124.

6. Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C*, Yan J*; Gao, GF*. A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS. Cell. 2020, 182 (3): 722-733.

7. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K, Wang Q, Zhou H, Yan J*, Qi J*. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020, 181:894-904.

8. Shi R, Chai Y, Duan X, Bi X, Huang Q, Wang Q, Tan S, Gao GF, Zhu J*, Yan J*. The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. Signal Transduction and Targeted Therapy. 2020, 5(1):16. 

9. Wang Q, Ma T, Wu Y, Chen Z, Zeng H, Tong Z, Gao F, Qi J, Zhao Z, Chai Y, Yang H, Wong G, Bi Y, Wu L, Shi R, Yang M, Song J, Jiang H, An Z, Wang J, Yilma TD, Shi Y, Liu WJ, Liang M, Qin C, Gao GF*, Yan J*. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nature Microbiology. 2019, 4(7):1231-1241

10. Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, Wang Q, Lu X, Wu Y, Liu W, Zhang B, Yuen KY, Perlman S, Gao GF*, Yan J *. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Research. 2015, 25(11):1237-49